Literature DB >> 8690288

Association of allele-specific HLA expression and histopathologic progression of cervical carcinoma.

W J van Driel1, M Y Tjiong, C G Hilders, B J Trimbos, G J Fleuren.   

Abstract

Immunohistochemical studies have shown that loss of HLA expression is observed in cervical carcinomas but not in premalignant CIN lesions, indicating that downregulation of HLA is linked to tumor progression. The present study was performed to investigate whether the degree of HLA expression in cervical cancer correlates with more advanced disease as defined by histopathological features. Frozen tissue sections from 49 patients with squamous carcinoma of the cervix FIGO stage IB to IIB were stained with HLA class I monomorphic, locus- and allele-specific monoclonal antibodies. Histological data indicative of local disease, i.e., depth of invasion, tumor size, stage, and systemic spread of the disease, such as tumor-positive lymph nodes, were collected by reviewing the histological slides. Univariate analysis revealed that loss of HLA-A locus and A2-allele expression showed a positive, significant correlation with both presence of tumor-positive lymph nodes (P = 0.04 and 0.02, respectively) and the number of lymph nodes involved (both P = 0.04). These results strongly support the idea that, specifically in an immunogenic cancer type such as cervical cancer, tumor cells escape immunosurveillance and gain growth advantage by allele-specific downregulation of the HLA-A2 molecule. In view of the development of immunotherapeutical interventions in cancer, upregulation of HLA class I molecules may prove to be a useful additional tool in the combat against immunogenic tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8690288     DOI: 10.1006/gyno.1996.0186

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  Immunosuppressive tumor microenvironment in cervical cancer patients.

Authors:  Sytse J Piersma
Journal:  Cancer Microenviron       Date:  2011-05-31

2.  Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial.

Authors:  Alessandro D Santin; Stefania Bellone; Michela Palmieri; Alessandro Zanolini; Antonella Ravaggi; Eric R Siegel; Juan J Roman; Sergio Pecorelli; Martin J Cannon
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

3.  Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML.

Authors:  Roger Mulet-Lazaro; Stanley van Herk; Claudia Erpelinck; Eric Bindels; Mathijs A Sanders; Carlo Vermeulen; Ivo Renkens; Peter Valk; Ari M Melnick; Jeroen de Ridder; Michael Rehli; Claudia Gebhard; Ruud Delwel; Bas J Wouters
Journal:  Blood       Date:  2021-07-15       Impact factor: 25.476

4.  Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer.

Authors:  L A Koopman; W E Corver; A R van der Slik; M J Giphart; G J Fleuren
Journal:  J Exp Med       Date:  2000-03-20       Impact factor: 14.307

Review 5.  Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.

Authors:  Karthik Dhatchinamoorthy; Jeff D Colbert; Kenneth L Rock
Journal:  Front Immunol       Date:  2021-03-09       Impact factor: 7.561

6.  Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma.

Authors:  Akash M Mehta; Ekaterina S Jordanova; Gemma G Kenter; Soldano Ferrone; Gert-Jan Fleuren
Journal:  Cancer Immunol Immunother       Date:  2007-07-12       Impact factor: 6.968

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.